

## REMARKS

Claims 1-39, as amended, appear in this application for the Examiner's review and consideration.

Claim 18 has been amended to depend from claim 1. Also, claims 18 and 37 have been amended to recite the administration of the peptide with an optional pharmaceutically acceptable carrier. As no new matter has been introduced, these claim amendments should be entered at this time.

In response to the Examiner's restriction requirement, applicants elect the invention of Group I, claims 1-17 and 39, for examination at this time. Thus, applicants expressly reserve the right to file a divisional application for the subject matter of original claims 18-38. In addition, although claims 18-38 are currently withdrawn from consideration, it is noted that these claims depend from claim 1 so that they should be re-joined and allowed when claim 1 is allowed.

With regard the election of species, applicants elect the structure of Formula 10. Accordingly, claims 1-3, 8-10, 13-17 and 39 should be actively examined at this time. The Examiner is reminded that if the elected species cannot be found after a prior art search, then the search must be expanded to include other species, i.e., those defined by other formulae such as those of formulae 6, 7, 8, and 9.


Finally, the Examiner species restriction between the structures and their cyclized analogs is traversed. Since the structures are the same except for the addition of a bridge, there would be no additional burden to search for such structures, since the backbone is the same.

Any further questions regarding this matter can be directed to the undersigned attorney of record.

Respectfully submitted,

Date: \_\_\_\_\_

1/27/06



Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN  
CUSTOMER NO. 28765

(212) 294-3311